|
| Georgina V Long | Melanoma Institute Australia The University of Sydney Richard F. Kefford, Melanoma Institute Australia The University of Sydney Macquarie University, Sydney Westmead Hospital, Moffitt Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology Kevin B. Kim, California Pacific Medical Center Adil Daud, University of California, The Angeles Clinic and Research Institute, University of Colorado Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Vanderbilt University Medical Center, University of Pennsylvania Abramson Cancer Center Nageatte Ibrahim, Incyte Corporation, Massachusetts General Hospital Cancer Center |
| Rene Gonzalez | Melanoma Institute Australia The University of Sydney Richard F. Kefford, Melanoma Institute Australia The University of Sydney Macquarie University, Sydney Westmead Hospital, Moffitt Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology Kevin B. Kim, California Pacific Medical Center Adil Daud, University of California, The Angeles Clinic and Research Institute, University of Colorado Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Vanderbilt University Medical Center, University of Pennsylvania Abramson Cancer Center Nageatte Ibrahim, Incyte Corporation, Massachusetts General Hospital Cancer Center |
| Jonathan Cebon | Melanoma Institute Australia The University of Sydney Richard F. Kefford, Melanoma Institute Australia The University of Sydney Macquarie University, Sydney Westmead Hospital, Moffitt Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology Kevin B. Kim, California Pacific Medical Center Adil Daud, University of California, The Angeles Clinic and Research Institute, University of Colorado Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Vanderbilt University Medical Center, University of Pennsylvania Abramson Cancer Center Nageatte Ibrahim, Incyte Corporation, Massachusetts General Hospital Cancer Center |